Cargando…

Lenvatinib for large hepatocellular carcinomas with portal trunk invasion: Two case reports

BACKGROUND: In a phase III trial of lenvatinib as first-line treatment for advanced unresectable hepatocellular carcinoma (uHCC), the drug proved non-inferior to sorafenib in terms of the overall survival, but offered better progression-free survival. However, the effects of lenvatinib in uHCC patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komiyama, Satoshi, Numata, Kazushi, Moriya, Satoshi, Fukuda, Hiroyuki, Chuma, Makoto, Maeda, Shin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7322437/ https://www.ncbi.nlm.nih.gov/pubmed/32607334 http://dx.doi.org/10.12998/wjcc.v8.i12.2574

Ejemplares similares

Therapeutic effects of regorafenib after sorafenib monotherapy with advanced hepatocellular carcinoma including Child–Pugh classification B: A retrospective observational study
por: Komiyama, Satoshi, et al.
Publicado: (2020)

Combination Therapy With Lenvatinib and Radiofrequency Ablation for Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh Class A Liver function: A Pilot Study
por: Wang, Feiqian, et al.
Publicado: (2022)

Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
por: Azuma, Shintaro, et al.
Publicado: (2020)

A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma
por: Kobayashi, Satoshi, et al.
Publicado: (2022)

Author Correction: Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib
por: Azuma, Shintaro, et al.
Publicado: (2021)

Liver Injury and Use of Contrast-Enhanced Ultrasound for Evaluating Intrahepatic Recurrence in a Case of TACE-Refractory Hepatocellular Carcinoma Receiving Atezolizumab-Bevacizumab Combination Therapy: A Case Report
por: Komiyama, Satoshi, et al.
Publicado: (2021)

Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression
por: Kondo, Masaaki, et al.
Publicado: (2017)

Sofosbuvir-based therapies associated with regression of liver fibrosis in patients with hepatitis C virus infection: A prospective observational study
por: Nozaki, Akito, et al.
Publicado: (2021)

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
por: He, Xiaoping, et al.
Publicado: (2022)

Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma
por: Chuma, Makoto, et al.
Publicado: (2020)

The change rate in serum nitric oxide may affect lenvatinib therapy in hepatocellular carcinoma
por: Kawamura, Atsushi, et al.
Publicado: (2022)

Comparative study between sorafenib and lenvatinib as the first‐line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real‐world setting
por: Fukushima, Taito, et al.
Publicado: (2021)

Comparison of vascularity observed using contrast-enhanced 3D ultrasonography and pathological changes in patients with hepatocellular carcinoma after sorafenib treatment
por: Fukuda, Hiroyuki, et al.
Publicado: (2018)

Use of Contrast-Enhanced Ultrasound with Sonazoid for Evaluating the Radiotherapy Efficacy for Hepatocellular Carcinoma
por: Funaoka, Akihiro, et al.
Publicado: (2021)

Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0–B1 hepatocellular carcinoma
por: Wang, Feiqian, et al.
Publicado: (2021)

Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4–B1: a pilot study
por: Wang, Feiqian, et al.
Publicado: (2021)

Safety and Efﬁcacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis
por: Ogushi, Katsuaki, et al.
Publicado: (2020)

Real impact of tumor marker AFP and PIVKA-II in detecting very small hepatocellular carcinoma (≤ 2 cm, Barcelona stage 0) - assessment with large number of cases
por: Tarao, Kazuo, et al.
Publicado: (2020)

Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment
por: Chuma, Makoto, et al.
Publicado: (2022)

Usefulness of 3D slicer for the planning and monitoring of hepatocellular carcinoma treatment using FUS
por: Doba, Nobutaka, et al.
Publicado: (2015)

Long‐term antitumor effect of lenvatinib on unresectable hepatocellular carcinoma with portal vein invasion
por: Takeda, Haruhiko, et al.
Publicado: (2019)

Respiratory motion tracking system of hepatocellular carcinoma treatment using FUS
por: Fukuda, Hiroyuki, et al.
Publicado: (2015)

Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma
por: Hao, Yoshiteru, et al.
Publicado: (2017)

Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study
por: Li, Shu-Qun, et al.
Publicado: (2023)

Comparison of unenhanced magnetic resonance imaging and ultrasound in detecting very small hepatocellular carcinoma
por: Tarao, Kazuo, et al.
Publicado: (2021)

Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Fukushima, Taito, et al.
Publicado: (2023)

Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression
por: Zhang, Ying, et al.
Publicado: (2022)

Novel clip device for prevention of bleeding after endoscopic papillectomy
por: Miwa, Haruo, et al.
Publicado: (2021)

Diagnostic Value of Imaging Methods in the Histological Four Grading of Hepatocellular Carcinoma
por: Wang, Feiqian, et al.
Publicado: (2020)

Conversion hepatectomy for advanced hepatocellular carcinoma after right portal vein transection and lenvatinib therapy
por: Ohya, Yuki, et al.
Publicado: (2020)

Two Cases of Intraabdominal Bleeding Caused by Hepatocellular Carcinoma Rupture Soon after the Initiation of Chemotherapy with Lenvatinib
por: Sato, Aya, et al.
Publicado: (2022)

Impact of lenvatinib on renal function compared to sorafenib for unresectable hepatocellular carcinoma
por: Sasaki, Ryu, et al.
Publicado: (2022)

A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus
por: Li, Xiaomi, et al.
Publicado: (2023)

Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study
por: Ji, Xiaoquan, et al.
Publicado: (2023)

Vascular Normalization Caused by Short-Term Lenvatinib Could Enhance Transarterial Chemoembolization in Hepatocellular Carcinoma
por: Tachiiri, Tetsuya, et al.
Publicado: (2023)

A case of Vp4 hepatocellular carcinoma with tumor thrombosis extending into the confluence of the splenic/portal vein achieved a good prognosis with emergent hepatectomy and postoperative adjuvant therapy with lenvatinib
por: Kato, Hiroyuki, et al.
Publicado: (2022)

Abdominal Ultrasound and Treatment of Hepatocellular Carcinoma
por: Numata, Kazushi
Publicado: (2021)

Hepatocellular Carcinoma Rupture after Introducing Lenvatinib: An Autopsy Case Report
por: Kohya, Risako, et al.
Publicado: (2022)

Multiple-line Chemotherapy for a Patient with Unresectable Mucinous Cystic Neoplasm of the Pancreas
por: Miwa, Haruo, et al.
Publicado: (2021)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tc8vh60japd7207pugd62cj5tn